Business Context and Reporting Period
This Form 8-K Current Report is filed by Global Medical REIT Inc. (not Chiron Real Estate Inc.) on December 11, 2019. The filing reports the entry into a material definitive agreement regarding a public equity offering.
Key Financial Metrics and Transaction Details
- Offering Size: 6,000,000 shares of Common Stock.
- Public Offering Price: $13.00 per share.
- Price to Company: $12.415 per share.
- Expected Gross Proceeds: $78.0 million.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 900,000 additional shares.
- Existing Debt: As of September 30, 2019, the Company had $363.2 million in borrowings outstanding under its Credit Facility.
- Debt Terms: Floating rate based on LIBOR plus a margin; facility expires August 7, 2022, with a one-year extension option.
Material Changes and Use of Proceeds
The primary material change is the execution of an Underwriting Agreement to raise capital. The Company intends to contribute net proceeds to its Operating Partnership. The Operating Partnership plans to use these funds to:
- Repay a portion of outstanding indebtedness under its Credit Facility.
- Fund future acquisitions.
- Support other general corporate purposes.
The filing notes that amounts repaid under the Credit Facility may be re-borrowed in the future to fund the capital program.
Guidance, Outlook, and Risks
Closing Date: The Offering is expected to close on December 13, 2019.
Risks and Contingencies: The Underwriting Agreement includes customary representations, warranties, and indemnification provisions where the Company agrees to indemnify Underwriters against certain liabilities under the Securities Act. The filing does not provide specific forward-looking financial guidance beyond the intended use of proceeds.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after underwriting discounts.
- Confirm the exact amount of debt repaid from the Credit Facility using the proceeds.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific termination provisions and conditions.
- Monitor whether the underwriters exercise the 900,000 share over-allotment option within 30 days.
- Check subsequent filings for updates on the Company's leverage ratio post-repayment.